Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent.
OBJECTIVE
Can biochip arrays identify which individuals with metastatic disease will respond to an anti-metastatic agent?


METHODS
Cytokine and cell adhesion arrays (Randox Ltd) were measured over 1 month in 9 research participants receiving CTCE-9908 in a Phase I/II study.


RESULTS
Research participants with stable disease (n=2) had significantly higher soluble VCAM-1 as compared to those that progressed.


CONCLUSIONS
VCAM-1 measurement early during CTCE-9908 treatment might be used as a surrogate for response.
Kavsak
Peter A
PA
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada. kavsakp@mcmaster.ca
Henderson
Matthew
M
Moretto
Patricia
P
Hirte
Hal
H
Evans
Ken
K
Wong
Donald
D
Korz
Walter
W
Hotte
Sebastien J
SJ
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D015815:Cell Adhesion Molecules / Q000097:blood; D016207:Cytokines / Q000097:blood; D003710:Demography; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D040081:Protein Array Analysis / Q000379:methods*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C540323:CTCE-9908; D015815:Cell Adhesion Molecules; D016207:Cytokines; D010455:Peptides